Literature DB >> 28039524

Effects of cyclic nucleotide phosphodiesterases (PDEs) on mitochondrial skeletal muscle functions.

Liliane Tetsi1, Anne-Laure Charles1, Stéphanie Paradis1, Anne Lejay1, Samy Talha1, Bernard Geny1, Claire Lugnier2.   

Abstract

Mitochondria play a critical role in skeletal muscle metabolism and function, notably at the level of tissue respiration, which conduct muscle strength as well as muscle survival. Pathological conditions induce mitochondria dysfunctions notably characterized by free oxygen radical production disturbing intracellular signaling. In that way, the second messengers, cyclic AMP and cyclic GMP, control intracellular signaling at the physiological and transcription levels by governing phosphorylation cascades. Both nucleotides are specifically and selectively hydrolyzed in their respective 5'-nucleotide by cyclic nucleotide phosphodiesterases (PDEs), which constitute a multi-genic family differently tissue distributed and subcellularly compartmentalized. These PDEs are presently recognized as therapeutic targets for cardiovascular, pulmonary, and neurologic diseases. However, very few data concerning cyclic nucleotides and PDEs in skeletal muscle, specifically in mitochondria, are reported in the literature. The knowledge of PDE implication in mitochondrial signaling would be helpful for resolving critical mitochondrial dysfunctions in skeletal muscle.

Entities:  

Keywords:  Cyclic AMP; Cyclic GMP; Cyclic nucleotide phosphodiesterase; Mitochondria functions; Skeletal muscle

Mesh:

Substances:

Year:  2016        PMID: 28039524     DOI: 10.1007/s00018-016-2446-0

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  87 in total

1.  Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum.

Authors:  V K Gopal; S H Francis; J D Corbin
Journal:  Eur J Biochem       Date:  2001-06

2.  Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases.

Authors:  Sung-Jun Park; Faiyaz Ahmad; Andrew Philp; Keith Baar; Tishan Williams; Haibin Luo; Hengming Ke; Holger Rehmann; Ronald Taussig; Alexandra L Brown; Myung K Kim; Michael A Beaven; Alex B Burgin; Vincent Manganiello; Jay H Chung
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

Review 3.  Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3).

Authors:  E Degerman; P Belfrage; V C Manganiello
Journal:  J Biol Chem       Date:  1997-03-14       Impact factor: 5.157

4.  Cyclic phosphodiesterase activity and the action of papaverine.

Authors:  L Triner; Y Vulliemoz; I Schwartz; G G Nahas
Journal:  Biochem Biophys Res Commun       Date:  1970-07-13       Impact factor: 3.575

Review 5.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

Review 6.  PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer.

Authors:  Anindita Das; David Durrant; Fadi N Salloum; Lei Xi; Rakesh C Kukreja
Journal:  Pharmacol Ther       Date:  2014-10-31       Impact factor: 12.310

Review 7.  cAMP signaling in skeletal muscle adaptation: hypertrophy, metabolism, and regeneration.

Authors:  Rebecca Berdeaux; Randi Stewart
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-02-21       Impact factor: 4.310

8.  Pentoxifylline inhibits Ca2+-dependent and ATP proteasome-dependent proteolysis in skeletal muscle from acutely diabetic rats.

Authors:  Amanda Martins Baviera; Neusa Maria Zanon; Luiz Carlos Carvalho Navegantes; Renato Hélios Migliorini; Isis do Carmo Kettelhut
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-10-31       Impact factor: 4.310

9.  Ischemic preconditioning specifically restores complexes I and II activities of the mitochondrial respiratory chain in ischemic skeletal muscle.

Authors:  Fabien Thaveau; Joffrey Zoll; Olivier Rouyer; Nabil Chafke; Jean Georges Kretz; Francois Piquard; Bernard Geny
Journal:  J Vasc Surg       Date:  2007-09       Impact factor: 4.268

10.  Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits.

Authors:  Fadi N Salloum; Ramzi A Ockaili; Michael Wittkamp; Vijay R Marwaha; Rakesh C Kukreja
Journal:  J Mol Cell Cardiol       Date:  2006-02-09       Impact factor: 5.000

View more
  5 in total

Review 1.  Hydrogen sulfide pathway and skeletal muscle: an introductory review.

Authors:  Valentina Vellecco; Chiara Armogida; Mariarosaria Bucci
Journal:  Br J Pharmacol       Date:  2018-06-15       Impact factor: 8.739

2.  Role of Cyclic Nucleotide Phosphodiesterases in Inner Ear and Hearing.

Authors:  Rahul Mittal; Nicole Bencie; Noah Shaikh; Jeenu Mittal; Xue Zhong Liu; Adrien A Eshraghi
Journal:  Front Physiol       Date:  2017-11-09       Impact factor: 4.566

Review 3.  PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking.

Authors:  Claire Lugnier; Hayder M Al-Kuraishy; Eric Rousseau
Journal:  Biochem Pharmacol       Date:  2021-01-28       Impact factor: 6.100

4.  An Update on Phosphodiesterase Mutations Underlying Genetic Etiology of Hearing Loss and Retinitis Pigmentosa.

Authors:  Rahul Mittal; Nicole Bencie; James M Parrish; George Liu; Jeenu Mittal; Denise Yan; Xue Zhong Liu
Journal:  Front Genet       Date:  2018-02-08       Impact factor: 4.599

Review 5.  COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors.

Authors:  Hayder M Al-Kuraishy; Ali I Al-Gareeb; Marwa S Al-Niemi; Ali K Al-Buhadily; Nasser A Al-Harchan; Claire Lugnier
Journal:  J Microsc Ultrastruct       Date:  2020-12-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.